Basic pharmacology of NMDA receptors

Current Pharmaceutical Design

Volumn 18, Issue 12, 2012, Pages 1558-1567

  Gonda, Xenia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Glutamate; Neuropsychiatric disorders; NMDA; Receptor subunits

Indexed keywords

DIMEBON; DIZOCILPINE; IFENPRODIL; IONOTROPIC RECEPTOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERAMEXANE; TRAXOPRODIL;

ADDICTION; AFFECTIVE PSYCHOSIS; ALZHEIMER DISEASE; ARTICLE; AUTISM; BRAIN ISCHEMIA; BREATHING; COGNITION; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; LEARNING; LOCOMOTION; MEMORY; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN DISEASES; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84860210195     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799958521     Document Type: Article

References (102)

1. [AM, Ed. Biology of the NMDA receptor. Boca Raton: CRC Press 2009.
2. Dubner R. The neurobiology of persistent pain and its clinical implications. Suppl Clin Neurophysiol 2004; 57: 3-7.
3. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33: 523-533.
4. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neurosci-entist 2005; 11: 37-49.
5. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci USA 2001; 98: 11042-11046.
6. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007; 7: 48-55.
7. Monaghan DT, Jane DE. Pharmacology of NMDA receptors. In: VanDongen AM, Ed. Biology if the NMDA receptor. Boca Raton: CRC Press 2009; pp. 257-283.
8. Asztely F, Gustafsson B. Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Mol Neurobiol 1996; 12: 1-11.
9. 2+ of NMDA responses in spinal cord neurones. Nature 1984; 309: 261-263.
10. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989; 29: 365-402.
11. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Third Edition: cambridge University Press; 2008.
12. Huang YH, Bergles DE. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 2004; 14: 346-352.
13. Wu LJ, Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 2009; 6: 693-702.
14. MacDonald JF, Mody I, Salter MW. Regulation of N-methyl-D-aspartate receptors revealed by intracellular dialysis of murine neurones in culture. J Physiol 1989; 414: 17-34.
15. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992; 258: 597-603.
16. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 2009; 157: 1301-1317.
17. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007; 7: 39-47.
18. Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 1999; 59: 279-298.
19. O'Hara PJ, Sheppard PO, Thogersen H, et al. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993; 11: 41-52.
20. Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 2005; 25: 308-317.
21. Stern-Bach Y, Bettler B, Hartley M, Sheppard PO, O'Hara PJ, Heinemann SF. Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron 1994; 13: 1345-1357.
22. Hirai H, Kirsch J, Laube B, Betz H, Kuhse J. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci USA 1996; 93: 6031-6036.
23. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997; 18: 493-503.
24. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34: 1219-1237.
25. Chatterton JE, Awobuluyi M, Premkumar LS, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002; 415: 793-798.
26. Wood MW, VanDongen HM, VanDongen AM. An alanine residue in the M3-M4 linker lines the glycine binding pocket of the N-methyl-D-aspartate receptor. J Biol Chem 1997; 272: 3532-3537.
27. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11: 327-335.
28. Monyer H, Sprengel R, Schoepfer R, et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992; 256: 1217-1221.
29. Liu L, Wong TP, Pozza MF, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004; 304: 1021-1024.
30. Bartlett TE, Bannister NJ, Collett VJ, et al. Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. Neuropharma-cology 2007; 52: 60-70.
31. Krupp JJ, Vissel B, Heinemann SF, Westbrook GL. Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific. Mol Pharmacol 1996; 50: 1680-1688.
32. Das S, Sasaki YF, Rothe T, et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998; 393: 377-381.
33. Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006; 439: 988-992.
34. Laurie DJ, Bartke I, Schoepfer R, Naujoks K, Seeburg PH. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res Mol Brain Res 1997; 51: 23-32.
35. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7: 742-755.
36. Watkins JC. Pharmacology of excitatory amino acid transmitters. Adv Biochem Psychopharmacol 1981; 29: 205-212.
37. Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981; 21: 165-204.
38. Marvizon JC, Lewin AH, Skolnick P. 1-Aminocyclopropane car-boxylic acid: a potent and selective ligand for the glycine modula-tory site of the N-methyl-D-aspartate receptor complex. J Neuro-chem 1989; 52: 992-994.
39. Hood WF, Sun ET, Compton RP, Monahan JB. 1-Aminocyclobutane-1-carboxylate (ACBC): a specific antagonist of the N-methyl-D-aspartate receptor coupled glycine receptor. Eur J Pharmacol 1989; 161: 281-282.
40. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989; 52: 1319-1328.
41. Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem 1994; 37: 4053-4067.
42. Henson MA, Roberts AC, Perez-Otano I, Philpot BD. Influence of the NR3A subunit on NMDA receptor functions. Prog Neurobiol 2010; 91: 23-37.
43. Evans RH, Francis AA, Watkins JC. Selective antagonism by Mg2+ of amino acid-induced depolarization of spinal neurones. Experientia 1977; 33: 489-91.
44. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology 1999; 38: 735-767.
45. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-575.
46. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 1986; 83: 7104-7108.
47. Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 1990; 345: 347-350.
48. Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 1995; 268: 873-876.
49. Williams K, Romano C, Molinoff PB. Effects of polyamines on the binding of [3H]MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site. Mol Pharmacol 1989; 36: 575-581.
50. Williams K, Dawson VL, Romano C, Dichter MA, Molinoff PB. Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. Neuron 1990; 5: 199-208.
51. Benveniste M, Mayer ML. Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippo-campal neurones. J Physiol 1993; 464: 131-163.
52. Williams K. Mechanisms influencing stimulatory effects of sper-mine at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol 1994; 46: 161-168.
53. 2+: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology 1994; 33: 935-952.
54. Peters S, Koh J, Choi DW. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science 1987; 236: 589-593.
55. Chen N, Moshaver A, Raymond LA. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol Pharmacol 1997; 51: 1015-1023.
56. Legendre P, Westbrook GL. Ifenprodil blocks N-methyl-D-aspartate receptors by a two-component mechanism. Mol Pharmacol 1991; 40: 289-298.
57. Kew JN, Trube G, Kemp JA. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br J Pharmacol 1998; 123: 463-472.
58. Williams K, Russell SL, Shen YM, Molinoff PB. Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 1993; 10: 267-278.
59. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006; 6: 68-74.
60. Borza I, Domany G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 2006; 6: 687-695.
61. Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol 2010; 225: 402-407.
62. Liu Y, Wong TP, Aarts M, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 2007; 27: 2846-2857.
63. Hynd MR, Scott HL, Dodd PR. Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J Neurochem 2004; 90: 913-919.
64. Hynd MR, Scott HL, Dodd PR. Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem 2004; 89: 240-247.
65. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-1058.
66. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723.
67. Bezprozvanny I. The rise and fall of Dimebon. Drug News Per-spect; 23: 518-523.
68. Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 2008; 23: 1860-1866.
69. Fernandes HB, Raymond LA. NMDA receptors and Huntington's Disease. In: VanDongen AM, Ed. Biology if the NMDA receptor. Boca Raton: CRC Press 2009; pp. 17-41.
70. Zeron MM, Hansson O, Chen N, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002; 33: 849-860.
71. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001; 276: 24713-24718.
72. Weinberger JM. Evolving therapeutic approaches to treating acute ischemic stroke. J Neurol Sci 2006; 249: 101-119.
73. Bennett M. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression. Aust N Z J Psychiatry 2009; 43: 711-721.
74. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002; 296: 692-695.
75. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436.
76. Morrison PD, Pilowsky LS. Schizophrenia: more evidence for less glutamate. Expert Rev Neurother 2007; 7: 29-31.
77. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959; 81: 363-369.
78. Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005; 78: 87-93.
79. Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008; 63: 6-8.
80. Becker S, Wojtowicz JM. A model of hippocampal neurogenesis in memory and mood disorders. Trends Cogn Sci 2007; 11: 70-76.
81. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the gluta-matergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
82. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
83. Zarate CA, Jr., Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-155.
84. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006; 31: 2405-2414.
85. Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsycho-pharmacology 2006; 31: 1659-1674.
86. Chen C, Hardy M, Zhang J, LaHoste GJ, Bazan NG. Altered NMDA receptor trafficking contributes to sleep deprivation-induced hippocampal synaptic and cognitive impairments. Bio-chem Biophys Res Commun 2006; 340: 435-440.
87. Maeng S, Zarate CA, Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9: 467-474.
88. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the anti-depressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008; 28: 631-637.
89. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30: 563-569.
90. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-1769.
91. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003; 99: 79-94.
92. 2+-insensitive mutants. Neuropharmacology 1995; 34: 347-355.
93. Nie Z, Madamba SG, Siggins GR. Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J Pharmacol Exp Ther 1994; 271: 1566-1573.
94. Wright JM, Peoples RW, Weight FF. Single-channel and whole-cell analysis of ethanol inhibition of NMDA-activated currents in cultured mouse cortical and hippocampal neurons. Brain Res 1996; 738: 249-256.
95. Calton JL, Wilson WA, Moore SD. Magnesium-dependent inhibition of N-methyl-D-aspartate receptor-mediated synaptic transmission by ethanol. J Pharmacol Exp Ther 1998; 287: 1015-1019.
96. Grover CA, Frye GD, Griffith WH. Acute tolerance to ethanol inhibition of NMDA-mediated EPSPs in the CA1 region of the rat hippocampus. Brain Res 1994; 642: 70-76.
97. Lai CC, Chang MC, Lin HH. Acute tolerance to ethanol inhibition of NMDA-induced responses in rat rostral ventrolateral medulla neurons. J Biomed Sci 2004; 11: 482-492.
98. Esel E. Neurobiology of alcohol withdrawal inhibitory and excitatory neurotransmitters. Turk Psikiyatri Derg 2006; 17: 129-137.
99. Hu XJ, Follesa P, Ticku MK. Chronic ethanol treatment produces a selective upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons. Brain Res Mol Brain Res 1996; 36: 211-218.
100. Cepeda C, André VM, Jocoy EL, Levine MS. NMDA and Dopa-mine: Diverse Mechanisms Applied to Interacting Receptor Systems. In: VanDongen AM, Ed. Biology if the NMDA receptor. Boca Raton: CRC Press 2009; pp. 41-59.
101. Vengeliene V, Bachteler D, Danysz W, Spanagel R. The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology 2005; 48: 822-829.
102. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998; 22: 802-809.